Spotlight on Oversold Healthcare Stocks: A Potential Investment Opportunity

In the healthcare sector, oversold stocks are catching the attention of investors looking for undervalued opportunities.

The Relative Strength Index (RSI) is a key momentum indicator used by traders to gauge stock performance. It compares how often a stock moves up in price against how often it moves down. Typically, when a stock’s RSI falls below 30, it is viewed as oversold, indicating potential for short-term gains, as highlighted by Benzinga Pro.

Below is a rundown of significant oversold stocks currently trading with an RSI of 30 or lower.

Silence Therapeutics PLC – ADR SLN

• Chardan Capital analyst Keay Nakae maintained a Buy rating on Silence Therapeutics with a price target of $55 as of December 10. However, the company’s stock has dropped approximately 41% in the past month, with a 52-week low recorded at $5.81.
• RSI Value: 26.72
• SLN Price Action: On Tuesday, Silence Therapeutics shares declined 3.4%, closing at $6.51.
• Recent updates about SLN were shared via Benzinga Pro’s real-time newsfeed.

ModivCare Inc MODV

• After reporting weaker-than-expected quarterly results on November 6, ModivCare’s stock reflected a decline of about 26% over five days. CEO L. Heath Sampson noted positive momentum in their operations despite market changes, with an adjusted EBITDA of $43 million and a 2% increase in consolidated revenue, primarily due to a 5% growth in personal care services. The company has a 52-week low of $11.00.
• RSI Value: 28.52
• MODV Price Action: Shares decreased by 11.4%, ending at $14.10 on Tuesday.
• Benzinga Pro’s charting tool revealed the recent trend for MODV stocks.

Olema Pharmaceuticals Inc OLMA

• On December 10, Olema Oncology presented new clinical results involving Palazestrant in conjunction with Ribociclib at the San Antonio Breast Cancer Symposium. The stock price has suffered a significant drop of around 37% over the past five days, with a 52-week low of $6.08.
• RSI Value: 23.69
• OLMA Price Action: Olema Pharmaceuticals shares fell 4.7%, ending at $6.14 on Tuesday.
• Benzinga Pro’s notifications suggested a potential breakout for OLMA shares.

Read This Next: